Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Drug

Nanjing Immunophage Biotech’s IPG11406 Approved for SLE Clinical Trial in China

Fineline Cube Jul 18, 2023

Nanjing Immunophage Biotech Co., Ltd, a China-based biotechnology company, has announced that it has received...

Company Deals

Pyrotech (Beijing) Biotechnology Secures $97.37 Million in Series A Financing

Fineline Cube Jul 18, 2023

China-based biotech firm Pyrotech (Beijing) Biotechnology Co., Ltd announced the successful completion of a CNY...

Company

Shanghai Henlius Biotech Announces Executive Leadership Changes

Fineline Cube Jul 18, 2023

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced significant changes in its executive leadership....

Company Drug

Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study

Fineline Cube Jul 18, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...

Company Deals

ObsEva SA Regains Full Rights to Nolasiban After Terminating Yuyuan Biological License Deal

Fineline Cube Jul 18, 2023

Swiss biopharmaceutical company ObsEva SA (SIX: OBSN) has announced that it has regained full rights...

Company Drug

Janssen’s Rybrevant Meets Primary Endpoint in Phase III NSCLC Study

Fineline Cube Jul 18, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced positive results from...

Company Drug

Antengene Corp., Ltd Receives Hong Kong NDA Approval for Xpovio in Relapsed Multiple Myeloma

Fineline Cube Jul 17, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced receiving New Drug Application (NDA)...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-A1811 and Pyrotinib Combo Study

Fineline Cube Jul 17, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...

Company Deals

Shanghai Xinhengrui Medical Technology Secures Series A Funding for Heart Failure Device Development

Fineline Cube Jul 17, 2023

Shanghai Xinhengrui Medical Technology Co., Ltd, a manufacturer of heart failure devices, has successfully raised...

Company Deals

Beyond Therapeutics Secures Tens of Millions in Pre-Series A Financing for Ophthalmology and Oncology Pipeline

Fineline Cube Jul 17, 2023

Beyond Therapeutics Co., Ltd., a biotechnology company based in Suzhou with a focus on ophthalmology...

Company Drug

Mabwell Bioscience Receives NMPA Approval to Launch 9MW2921 Clinical Study

Fineline Cube Jul 17, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that it...

Company Deals Hospital

Centre Medical Secures Tens of Millions in Series A Financing to Expand Globally

Fineline Cube Jul 17, 2023

Centre Medical, a Hong Kong-based cardiovascular specialized medical services provider, has reportedly raised tens of...

Company Drug

TransThera Sciences’ TT-00420 Receives Breakthrough Designation for Cholangiocarcinoma Treatment

Fineline Cube Jul 17, 2023

The Center for Drug Evaluation (CDE) website has indicated that Nanjing-based TransThera Sciences (Nanjing), Inc.’s...

Company Drug

Shenzhen Salubris Pharmaceuticals’ SAL0120 for IgA Nephropathy Accepted for NMPA Review

Fineline Cube Jul 17, 2023

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that the National Medical Products Administration...

Policy / Regulatory

NHSA Unveils 2023 Flying Inspection Plan for Medical Insurance Fund Oversigh

Fineline Cube Jul 17, 2023

The National Healthcare Security Administration (NHSA) has released its 2023 Basic Medical Insurance (BMI) Fund...

Company Drug

Betta Pharmaceuticals’ MCLA-129 Combo Therapy for NSCLC Gets NMPA Clinical Approval

Fineline Cube Jul 17, 2023

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that it has received clinical trial...

Company Drug

Pfizer Launches Phase III Trial for Quadrivalent Influenza modRNA Vaccine in Argentina

Fineline Cube Jul 17, 2023

Global pharmaceutical giant Pfizer (NYSE: PFE) has commenced recruitment in Argentina for a Phase III...

Company Drug

Zai Lab Initiates Phase III Trial for Bemarituzumab in First-Line Gastric Cancer Treatment

Fineline Cube Jul 17, 2023

China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the first patient...

Company Drug Policy / Regulatory

Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis

Fineline Cube Jul 17, 2023

Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its...

Company Deals

Silence Therapeutics Receives $4 Million Milestone Payment from Hansoh Pharmaceutical

Fineline Cube Jul 14, 2023

UK-based Silence Therapeutics plc (NASDAQ: SLN) has announced the receipt of a $4 million milestone...

Posts pagination

1 … 554 555 556 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.